M. J. Juan-Fita

Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma.

Enfortumab vedotin plus pembrolizumab and erdafitinib have transformed the treatment of locally advanced or metastatic urothelial carcinoma (la/mUC) but are associated with distinct and, in some cases, overlapping toxicities that may lead to treatment discontinuation and impaired clinical outcomes if not recognised and...